“…Additionally, ligands for NK cell activating receptors are often upregulated on tumor cells or during infection (Miller and Lanier, 2019), and the loss of these ligands reduces NK cell recognition and killing. Notably, the NK cell activating ligands MHC class I polypeptide-related sequence A/B (MICA/B) are often downregulated by diverse tumors including leukemia; prostate cancer; melanoma; and breast, lung, ovarian, and colon carcinomas, leading to decreased engagement of the NK cell activating receptor NKG2D and decreased anti-tumor activity (Lanier, 2019). Additionally, NKG2D ligands can be secreted by tumor cells, leading to impaired NK cell function (Ashiru et al, 2010;Clayton et al, 2008;Hedlund et al, 2011;Lundholm et al, 2014).…”